Announcements Trials
Browse Landscape

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 71Observational 2Expanded_access 1

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 1Neuroendocrine Tumor Grade 3 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × surufatinib × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Unknown
32 enrolled
EndocrineNET

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡